ERAS / Goldman Sachs Maintains Erasca Buy Recommendation

Fintel reports that on May 16, 2023, Goldman Sachs maintained coverage of Erasca (NASDAQ:ERAS) with a Buy recommendation. more_horizontal

Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down more_horizontal

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoverin more_horizontal

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoverin more_horizontal

SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoveri more_horizontal

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal